Tofacitinib Demonstrates Sustained Improvement in RA
Medical Health News,
In an article published in a recent edition of Arthritis Research
In an article published in a recent edition of Arthritis Research
Tofacitinib, either at 5 mg or 10 mg twice daily, maintains its safety profile for at least 9.5 years, with sustained efficacy…
medwireNews : The Janus kinase (JAK) inhibitor tofacitinib has demonstrated a consistent safety profile and sustained efficacy…
medwireNews: The Janus kinase (JAK) inhibitor tofacitinib has demonstrated a consistent safety profile and sustained efficacy…